EZH2 and non-small cell lung carcinoma: Furthermore, EZH2 regulates the promoter region of cyclin-dependent kinase inhibitor 1C (CDKN1C) H3K27me3 methylation, promoting its transcriptional silencing and driving NSCLC and SCLC resistance to cisplatin (70, 71).